for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Corcept Therapeutics Incorporated

CORT.OQ

Latest Trade

13.99USD

Change

0.00(0.00%)

Volume

134,962

Today's Range

13.69

 - 

14.05

52 Week Range

9.14

 - 

19.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.99
Open
13.92
Volume
134,962
3M AVG Volume
15.30
Today's High
14.05
Today's Low
13.69
52 Week High
19.48
52 Week Low
9.14
Shares Out (MIL)
113.69
Market Cap (MIL)
1,579.14
Forward P/E
18.56
Dividend (Yield %)
--

Next Event

Q3 2019 Corcept Therapeutics Inc Earnings Release

Latest Developments

More

Corcept Therapeutics Reports Q2 Non-GAAP Earnings Per Share Of $0.25

Corcept Therapeutics Reports Q2 GAAP Earnings Per Share of $0.17

Corcept Therapeutics says Received Paragraph IV Notice Letter Advising Sun Pharmaceutical Industries Submitted ANDA To U.S. FDA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Industry

Biotechnology & Drugs

Contact Info

149 Commonwealth Dr

+1.650.3273270

http://www.corcept.com/

Executive Leadership

James N. Wilson

Independent Chairman of the Board

Joseph K. Belanoff

President, Chief Executive Officer, Director

Gary Charles Robb

Chief Financial Officer, Secretary

Sean Maduck

Senior Vice President - Commercial

Andreas Grauer

Chief Medical Officer

Key Stats

2.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.3K

2019(E)

0.3K
EPS (USD)

2016

0.070

2017

0.420

2018

0.600

2019(E)

0.738
Price To Earnings (TTM)
22.06
Price To Sales (TTM)
5.88
Price To Book (MRQ)
5.30
Price To Cash Flow (TTM)
20.09
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
28.87
Return on Equity (TTM)
25.94

Latest News

Latest News

BRIEF-Corcept Therapeutics Reports Qtrly Revenue $57.7 Million

* CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals For Infringement Of Korlym Patents

* CORCEPT THERAPEUTICS FILES LAWSUIT AGAINST TEVA PHARMACEUTICALS FOR INFRINGEMENT OF KORLYM PATENTS

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application

* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA

BRIEF-Corcept Therapeutics, Dohmen Entered Into Settlement Agreement And Mutual Release Of Any And All Claims That May Have Existed Between Parties

* CORCEPT THERAPEUTICS - CO, DOHMEN ENTERED INTO SETTLEMENT AGREEMENT AND MUTUAL RELEASE OF ANY AND ALL CLAIMS THAT MAY HAVE EXISTED BETWEEN PARTIES

BRIEF-Corcept Therapeutics posts Q3 earnings per share $0.11

* Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update

BRIEF-Corcept Therapeutic says Dohmen Life Science Services filed a complaint alleging Corcept unlawfully terminated Dohmen agreement

* Corcept Therapeutics Inc - On August 7, 2017, Dohmen Life Science Services filed a complaint alleging corcept unlawfully terminated dohmen agreement

BRIEF-Corcept Therapeutics Q2 GAAP earnings per share $0.10

* Corcept Therapeutics announces second quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update

BRIEF-Corcept therapeutics Q1 GAAP earnings per share $0.04

* Corcept Therapeutics announces first quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update

BRIEF-Corcept Therapeutics files for mixed shelf of up to $200 mln

* In addition, 349,425 shares of co's common stock offered by the selling stockholders

BRIEF-Corcept Therapeutics posts Q4 earnings per share $0.04

* Corcept Therapeutics announces fourth quarter and full-year 2016 financial results; increases 2017 revenue guidance

BRIEF-Corcept Therapeutics reports Q4 preliminary GAAP earnings per share $0.04

* Corcept Therapeutics announces preliminary fourth quarter and full-year 2016 financial results and corporate update; provides 2017 revenue guidance

BRIEF-Corcept Therapeutics Q3 gaap earnings per share $0.02

* Says expects that its revenue for 2016 will be $79-82 million, an increase from its original guidance of $76-81 million

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up